For the quarter ending 2025-09-30, TG had $3,496K increase in cash & cash equivalents over the period. $16,512K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net income (loss) | 7,074 | 11,832 |
| Depreciation | 5,023 | 10,018 |
| Amortization of identifiable intangibles | 440 | 879 |
| Reduction of right-of-use lease asset | 520 | 1,064 |
| Deferred income taxes | 1,664 | 1,209 |
| Accrued pension and post-retirement benefits | 27 | 107 |
| Stock-based compensation expense | 840 | 919 |
| Gain on investment in kalo | 0 | 0 |
| Gain on the sale of assets | 5 | 1,492 |
| Gain on the sale of divested business | 0 | 9,657 |
| Accounts and other receivables | 9,097 | 14,016 |
| Inventories | -4,648 | 15,263 |
| Income taxes recoverable/payable | -238 | 349 |
| Prepaid expenses and other | 2,988 | -8,897 |
| Accounts payable and accrued expenses | 12,071 | 2,336 |
| Lease liability | 560 | 1,240 |
| Pension and postretirement benefit plan contributions | 139 | 291 |
| Other, net | 364 | 2,195 |
| Net cash provided by (used in) operating activities | 20,120 | -2,852 |
| Capital expenditures | 3,608 | 5,638 |
| Proceeds from the sale of terphane | 0 | 9,835 |
| Proceeds on sale of investment in kalo | 0 | 0 |
| Proceeds from the sale of assets | 0 | 1,904 |
| Net cash provided by (used in) investing activities | -3,608 | 6,101 |
| Borrowings | 15,550 | 88,197 |
| Debt principal payments | 28,679 | 87,494 |
| Debt financing costs | 0 | 1,272 |
| Net cash provided by (used in) financing activities | -13,129 | -569 |
| Effect of exchange rate changes on cash | 113 | 53 |
| Increase (decrease) in cash and cash equivalents | 3,496 | 2,733 |
| Cash and cash equivalents at beginning of period | 7,062 | - |
| Cash and cash equivalents at end of period | 13,291 | - |
TREDEGAR CORP (TG)
TREDEGAR CORP (TG)